Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL209 vs Trulicity add-on to metformin in type 2 diabetes
CTR20230850Phase 3Completed
- Sponsor
- Beijing SL Pharmaceutical
- Start
- Mar 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of SL209 in type 2 diabetes mellitus (T2DM), sponsored by Beijing SL Pharmaceutical. Started Mar 2023; status: completed.
02
Drugs
SL209
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20230850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230850.